Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Ionis Pharmaceuticals Inc Stock Research

IONS

42.48USD-0.06(-0.14%)Market Closed
Watchlist

Market Summary

USD42.48-0.06
Market Closed
-0.14%

IONS Alerts

  • Big jump in Revenue (Y/Y)
  • Losses in recent quarter

IONS Stock Price

IONS RSI Chart

IONS Valuation

Market Cap

6.1B

Price/Earnings (Trailing)

-19.71

Price/Sales (Trailing)

9.66

EV/EBITDA

-21.66

Price/Free Cashflow

-12.48

IONS Price/Sales (Trailing)

IONS Profitability

EBT Margin

-53.28%

Return on Equity

-67.59%

Return on Assets

-11.4%

Free Cashflow Yield

-8.02%

IONS Fundamentals

IONS Revenue

Revenue (TTM)

630.6M

Revenue Y/Y

40.82%

Revenue Q/Q

44.35%

IONS Earnings

Earnings (TTM)

-309.0M

Earnings Y/Y

18.88%

Earnings Q/Q

31.4%

Price Action

52 Week Range

47.74
(Low)(High)

Last 7 days

-1.4%

Last 30 days

8.5%

Last 90 days

3.3%

Trailing 12 Months

-8.5%

IONS Financial Health

Current Ratio

9.81

IONS Investor Care

Shares Dilution (1Y)

0.97%

Diluted EPS (TTM)

-2.17

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for IONS

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-08-31
Geary Richard S
acquired
30.5575
30.5575
1.00
officer level 14
2023-08-31
Monia Brett P
acquired
4,797
30.5575
157
ceo level 15
2023-08-31
BENNETT C FRANK
acquired
5,500
30.5575
180
officer level 14
2023-08-01
Diaz Allene M.
sold
-26,969
41.05
-657
-
2023-07-18
KLEIN JOSEPH III
sold
-149,310
42.00
-3,555
-
2023-07-17
BERTHELSEN SPENCER R
acquired
-
-
7,110
-
2023-07-17
Hayden Michael R
acquired
-
-
7,110
-
2023-07-17
Diaz Allene M.
acquired
-
-
5,333
-
2023-07-17
LOSCALZO JOSEPH
acquired
-
-
7,110
-
2023-07-17
KLEIN JOSEPH III
acquired
-
-
7,110
-

1–10 of 50

Which funds bought or sold IONS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-12
Farther Finance Advisors, LLC
added
58.33
4,559
10,134
-%
2023-09-06
Deep Track Capital, LP
unchanged
-
14,992,200
116,282,000
5.38%
2023-08-24
Alberta Investment Management Corp
sold off
-100
-3,624,960
-
-%
2023-08-23
Stonebridge Capital Advisors LLC
new
-
2,831
2,831
-%
2023-08-22
COMERICA BANK
new
-
6,000
6,000
-%
2023-08-22
VIRGINIA RETIREMENT SYSTEMS ET AL
added
51.09
601,192
1,419,640
0.01%
2023-08-21
BOKF, NA
reduced
-2.51
256,784
2,410,510
0.05%
2023-08-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-2.53
702,215
6,605,750
0.01%
2023-08-21
OSAIC HOLDINGS, INC.
reduced
-8.12
18,593
359,559
-%
2023-08-16
Nuveen Asset Management, LLC
added
8.79
2,792,740
14,009,700
-%

1–10 of 37

Latest Funds Activity

Are funds buying IONS calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own IONS
No. of Funds

Schedule 13G FIlings of Ionis Pharmaceuticals

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jun 09, 2023
vanguard group inc
10.07%
14,414,917
SC 13G/A
Feb 14, 2023
bb biotech ag
6.8%
9,635,000
SC 13G/A
Feb 14, 2023
t. rowe price investment management, inc.
8.2%
11,678,259
SC 13G
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 09, 2023
vanguard group inc
9.54%
13,546,694
SC 13G/A
Feb 01, 2023
blackrock inc.
6.5%
9,182,911
SC 13G/A
Apr 11, 2022
price t rowe associates inc /md/
10.1%
14,350,460
SC 13G/A
Feb 14, 2022
price t rowe associates inc /md/
8.8%
12,490,280
SC 13G/A
Feb 11, 2022
bb biotech ag
7.2%
10,232,973
SC 13G/A
Feb 10, 2022
vanguard group inc
8.50%
12,007,076
SC 13G/A

Recent SEC filings of Ionis Pharmaceuticals

View All Filings
Date Filed Form Type Document
Sep 05, 2023
4
Insider Trading
Sep 05, 2023
4
Insider Trading
Sep 05, 2023
4
Insider Trading
Aug 23, 2023
8-K
Current Report
Aug 22, 2023
8-K
Current Report
Aug 14, 2023
144/A
144/A
Aug 11, 2023
S-8
Employee Benefits Plan
Aug 09, 2023
8-K
Current Report
Aug 09, 2023
10-Q
Quarterly Report
Aug 04, 2023
8-K
Current Report

Peers (Alternatives to Ionis Pharmaceuticals)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
271.4B
56.0B
2.30% 9.45%
31.25
4.84
-2.31% -31.27%
265.4B
1.8B
-1.67% 25.43%
-153.19
146.56
69.45% 14.65%
90.8B
9.5B
0.45% 22.78%
26.99
9.56
13.83% 5.33%
89.0B
12.7B
-1.51% 18.09%
20.7
7.02
-10.94% -24.40%
21.9B
1.2B
-7.00% -17.21%
-20.61
17.72
39.94% -8.44%
11.0B
1.0B
3.70% 3.57%
-12.12
10.97
20.15% -79.16%
10.5B
2.1B
-3.12% 8.08%
12.05
4.98
18.01% 38.16%
MID-CAP
3.1B
225.6M
0.04% -28.00%
-5.53
13.59
-2.11% 21.02%
3.0B
-
-10.01% 147.80%
-9.03
-
- -28.88%
2.6B
402.9M
-2.14% -20.15%
-3.59
6.42
20.50% -42.46%
1.9B
27.2M
-14.18% -57.07%
-2.57
69.63
- -14.43%
SMALL-CAP
3.1B
-
-2.94% -39.70%
-7.31
33.28
34.30% -149.91%
1.3B
302.9M
-16.58% -4.84%
11.23
4.28
77.72% 112.02%
281.2M
152.5M
-11.67% 38.41%
37.75
1.84
127.84% 103.41%
29.9M
-
1.35% 3552.08%
-0.65
-
- -31.51%

Ionis Pharmaceuticals News

Nasdaq
The Math Shows VONV Can Go To $80.
Nasdaq,
10 hours ago
InvestorPlace
Seeking Alpha

Returns for IONS

Cumulative Returns on IONS

2.7%


7-Year Cumulative Returns

-2.8%


5-Year Cumulative Returns

-6.1%


3-Year Cumulative Returns

Risks for IONS

What is the probability of a big loss on IONS?

90%


Probability that Ionis Pharmaceuticals stock will be more than 20% underwater in next one year

55%


Probability that Ionis Pharmaceuticals stock will be more than 30% underwater in next one year.

21.1%


Probability that Ionis Pharmaceuticals stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does IONS drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Ionis Pharmaceuticals was unfortunately bought at previous high price.

Drawdowns

Financials for Ionis Pharmaceuticals

Income Statement (Last 12 Months)
Income Statement (Last 12 Months)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue9.5%630,591,000575,971,000587,367,000875,483,000848,809,000840,768,000810,456,000660,731,000687,717,000707,504,000729,264,000932,664,000940,477,000958,753,0001,122,599,000821,034,000798,537,000752,471,000599,674,000579,860,000552,779,000
Operating Expenses-------------------661,046,000653,707,000596,742,000
  S&GA Expenses7.6%174,024,000161,684,000150,295,000139,945,000136,622,000159,275,000186,347,000287,614,000324,968,000340,528,000354,322,000298,732,000290,321,000293,417,000286,644,000269,427,000278,103,000269,190,000244,622,000224,269,000182,345,000
EBITDA100.0%--286,018,000-235,535,00035,013,000-1,953,00020,852,000-4,312,000-208,291,000-156,341,000-126,141,000-89,562,000130,718,000175,359,000203,257,000387,534,000------
EBITDA Margin100.0%--0.50-0.400.040.000.02-0.01-0.32-0.23-0.18-0.120.140.190.210.35------
Interest Expenses2.1%7,769,0007,608,0008,122,0008,629,0008,830,0009,057,0009,349,0009,545,0009,633,0009,717,0009,510,000-15,888,000-6,314,0003,047,00012,440,00046,860,00046,140,00045,451,00044,789,00044,119,00043,662,000
Earnings Before Taxes8.3%-281,430,000-306,857,000-257,985,00011,261,000-25,803,000-3,476,000-29,148,000-268,633,000-216,410,000-171,338,000-134,552,000110,278,000145,345,000163,882,000338,766,000119,276,00095,846,00056,573,000-76,156,000-103,253,000-89,872,000
EBT Margin100.0%--0.53-0.440.01-0.030.00-0.04-0.41-0.31-0.24-0.180.120.150.170.30------
Net Income6.0%-309,035,000-328,880,000-269,722,0007,321,000-28,153,000-3,893,000-28,597,000-607,742,000-549,743,000-494,504,000-444,263,00094,684,000145,314,000170,074,000294,145,000429,808,000399,086,000359,604,000273,741,000-49,259,000-47,311,000
Net Income Margin100.0%--0.57-0.460.01-0.030.00-0.04-0.92-0.81-0.72-0.640.080.140.170.26------
Free Cashflow100.0%--400,200,000-290,091,000115,428,00086,502,00040,923,00018,844,000-89,513,000-52,684,000-38,998,000772,000178,114,000171,476,000193,675,000314,815,000------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets3.0%2,9712,8852,5342,4222,4562,5192,6122,4152,4972,2492,3903,0963,0793,0913,2332,8952,8782,8362,6682,2482,247
  Current Assets2.9%2,6172,5432,2032,1522,1912,2532,3452,1562,2381,9892,1312,5372,5312,5582,7212,4082,4142,3742,2082,0792,083
    Cash Equivalents37.5%425309276315522543869633565414398633530486683248273376279480805
  Inventory15.0%26.0022.0022.0021.0020.0024.0025.0023.0024.0022.0022.0022.0024.0023.0018.0019.0019.0011.009.008.00-
  Net PPE7.6%92.0085.0074.00181177178178180179180181182173164154149135134132132128
Liabilities6.0%2,5432,3991,9611,8281,8311,8101,8401,8841,9141,5681,6461,4891,4841,5211,5491,3971,4211,4481,4811,4081,430
  Current Liabilities11.1%288259312283268228241280294295599245231258273232241252280260249
Shareholder's Equity-12.0%4284875735946257107725315836817431,5211,5031,4721,5771,4981,4571,3871,101840817
  Retained Earnings-5.5%-1,639-1,553-1,429-1,377-1,330-1,225-1,159-1,384-1,302-1,221-1,131-909-878-846-707-857-883-882-967-1,287-1,282
  Additional Paid-In Capital1.4%2,1182,0892,0602,0352,0091,9831,9641,9421,9101,9261,8962,3122,2722,2342,2042,2192,1772,1182,0472,0302,012
Shares Outstanding0.1%143143142142142142141141141141140140139139140141140139138137129
Minority Interest------------223218210213162188180139130121
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations-21.0%-455-376-27413098.0054.0031.00-74.91-29.61-11.1836.00216213230346183170697603508563
  Share Based Compensation2.0%10310110097.00104109121193209227230170148142147146156148131120106
Cashflow From Investing24.2%-227-300-262-379-73.77-171195288268448274225124-66.11-41.27-505-814-1,079-929-657-500
Cashflow From Financing32.0%586444-55.29-66.77-67.14246246-213-203-509-596-55.90-80.01-53.9410090.00112530476470610
  Buy Backs----------0.0091.0012512512534.00------

IONS Income Statement

2023-06-30
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Revenue:    
Revenue$ 188,411$ 133,791$ 318,935$ 275,710
Expenses:    
Cost of sales2,5374,7453,8808,914
Research, development and patent229,927180,758427,740341,884
Selling, general and administrative46,14233,80291,65867,929
Total operating expenses278,606219,305523,278418,727
Loss from operations(90,195)(85,514)(204,343)(143,017)
Other income (expense):    
Investment income20,7923,40339,4195,396
Interest expense(2,291)(2,130)(3,899)(4,252)
Interest expense related to sale of future royalties(17,655)0(33,170)0
Gain (loss) on investments718(6,337)189(12,963)
Other income (expense)11,183(12,297)11,414(12,110)
Loss before income tax expense(77,448)(102,875)(190,390)(166,946)
Income tax expense(7,842)(2,260)(19,223)(3,354)
Net loss$ (85,290)$ (105,135)$ (209,613)$ (170,300)
Basic net loss per share (in dollars per share)$ (0.6)$ (0.74)$ (1.47)$ (1.2)
Diluted net loss per share (in dollars per share)$ (0.6)$ (0.74)$ (1.47)$ (1.2)
Shares used in computing basic net loss per share (in shares)143,098141,794142,918141,697
Shares used in computing diluted net loss per share (in shares)143,098141,794142,918141,697
Commercial Revenue [Member]    
Revenue:    
Revenue$ 77,897$ 78,184$ 145,664$ 150,468
SPINRAZA Royalties [Member]    
Revenue:    
Revenue61,01259,627111,258113,444
Other Commercial Revenue [Member]    
Revenue:    
Revenue16,88518,55734,40637,024
Research and Development Revenue [Member]    
Revenue:    
Revenue110,51455,607173,271125,242
Collaborative Agreement Revenue [Member]    
Revenue:    
Revenue91,01338,247129,34788,032
Eplontersen Joint Development Revenue [Member]    
Revenue:    
Revenue$ 19,501$ 17,360$ 43,924$ 37,210

IONS Balance Sheet

2023-06-30
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 424,790$ 276,472
Short-term investments1,960,5981,710,397
Contracts receivable27,95625,538
Inventories25,53822,033
Other current assets177,872168,254
Total current assets2,616,7542,202,694
Property, plant and equipment, net91,63474,294
Right-of-use assets176,718181,544
Deposits and other assets86,02575,344
Total assets2,971,1312,533,876
Current liabilities:  
Accounts payable24,02117,921
Accrued compensation29,32249,178
Accrued liabilities104,745140,101
Income taxes payable24,7326,249
Current portion of deferred contract revenue96,25290,577
Other current liabilities8,9037,535
Total current liabilities287,975311,561
Long-term deferred contract revenue254,398287,768
Liability related to sale of future royalties, net510,1740
Long-term lease liabilities175,020178,941
Long-term obligations16,43615,973
Total liabilities2,542,8301,960,989
Stockholders' equity:  
Common stock, $0.001 par value; 300,000,000 shares authorized, 143,167,414 and 142,057,736 shares issued and outstanding at June 30, 2023 (unaudited) and December 31, 2022, respectivel143142
Additional paid-in capital2,118,3092,059,850
Accumulated other comprehensive loss(50,913)(57,480)
Accumulated deficit(1,639,238)(1,429,625)
Total stockholders' equity428,301572,887
Total liabilities and stockholders' equity2,971,1312,533,876
1.75 Percent Convertible Senior Notes [Member]  
Current liabilities:  
Convertible senior notes, net560,9370
0 Percent Convertible Senior Notes [Member]  
Current liabilities:  
Convertible senior notes, net623,809622,242
0.125 Percent Convertible Senior Notes [Member]  
Current liabilities:  
Convertible senior notes, net$ 114,081$ 544,504
Brett P. Monia
660
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It is involved in developing neurology products that include Tominersen for Huntington's diseases; Tofersen for amyotrophic lateral sclerosis (ALS); IONIS-MAPTRx for Alzheimer's diseases; IONIS-C9Rx for genetic form of ALS; ION859 for Parkinson's disease; ION464 for multiple system atrophy and Parkinson's disease; ION541 for amyotrophic lateral sclerosis; and IONIS-DNM2-2.5Rx for centronuclear myopathy. The company is also developing products for cardiometabolic disease, such as IONIS-TTR-LRx for transthyretin amyloidosis and IONIS-GHR-LRx for acromegaly; IONIS-APOCIII-LRx for familial chylomicronemia syndrome and TG- driven diseases; IONIS-APOCIII-LRx for treatment resistant hypertension; Pelacarsen for Lp(a)cardiovascular disease risk reduction; Vupanorsen for sHTG/CVDRR; IONIS-FXI-LRx for clotting disorders; ION449 for cardiovascular diseases; and IONIS-GCGRRx for diabetics. In addition, it develops IONIS-ENAC-2.5Rx for cystic fibrosis and chronic obstructive pulmonary disease; IONIS-PKK-LRx for hereditary angioedema; Danvatirsen for cancer; IONIS-TMPRSS6-LRx for beta-thalassemia and iron toxicity; IONIS-HBVRx for hepatitis B virus; IONIS-AR-2.5Rx for prostate cancer; IONIS-FB-LRx for age-related macular degeneration and IgA nephropathy; and ION357 for retinitis pigmentosa. It has a collaboration agreement with AstraZeneca; GlaxoSmithKline plc; Janssen Biotech, Inc.; Bayer AG; Novartis AG; Pfizer, Inc.; Biogen Inc.; Flamingo Therapeutics, Inc.; and Roche. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.